Likewise, we were not able to demonstrate a statistically significant difference in BCL-2 protein expression level between CD34+ and CD34− AML patients, whereas others have shown that BCL-2 is maximally expressed in the CD34+ leukemic cell compartment, followed by a downregulation upon the loss of CD34 during differentiation [25,31,32]. This evidence concerns the gene CD34 and acute myeloid leukemia.